ZOTA - Zota Health Care
📢 Recent Corporate Announcements
Zota Health Care Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by Satellite Corporate Services Private Limited, confirms the processing of dematerialization requests for the quarter ended March 31, 2026. It verifies that physical share certificates were mutilated, cancelled, and replaced by the depository's name in the records within the prescribed 15-day limit. This is a standard administrative filing ensuring the company's adherence to shareholding record-keeping norms.
- Compliance certificate issued for the quarter ended March 31, 2026.
- Confirmation that dematerialization requests were processed within 15 days of receipt.
- Physical share certificates were duly mutilated and cancelled as per SEBI regulations.
- The Registrar and Share Transfer Agent (RTA) for the period was Satellite Corporate Services Private Limited.
Zota Health Care has issued a clarification to shareholders following a report from proxy advisory firm IiAS regarding a resolution to increase inter-corporate loan and investment limits. The company is seeking to raise the limit from ₹500 crores to ₹1,000 crores, noting that the previous limit approved in March 2025 has already been exhausted. Management justifies this increase as necessary for supporting the working capital needs of its subsidiary, Davaindia Health Mart, and for potential strategic acquisitions. The company maintains that all transactions will adhere to strict governance frameworks and statutory disclosure requirements.
- Proposed increase in Section 186 limits for loans, guarantees, and investments from ₹500 crores to ₹1,000 crores.
- The previous ₹500 crore limit approved on March 26, 2025, is already exhausted due to recent QIP-funded investments.
- A significant portion of the headroom is intended for Davaindia Health Mart Limited, a major revenue contributor.
- The response addresses concerns raised by Institutional Investor Advisory Services (IiAS) in their report dated March 27, 2026.
- Voting for this resolution via postal ballot is scheduled to conclude on April 16, 2026.
Zota Health Care Limited has addressed a clarification sought by the National Stock Exchange regarding its financial results for the quarter ended September 30, 2025. The company acknowledged a clerical error where comparative Balance Sheet data for March 2025 was mistakenly replaced with September 2024 data. Crucially, the management confirmed that there are no changes to the actual financial figures reported earlier. While standalone performance shows strong growth, the consolidated notes indicate significant losses in subsidiary operations.
- Corrected a clerical error in the Balance Sheet where March 2025 comparative data was missing in the original filing.
- Confirmed that all previously reported financial figures remain unchanged despite the filing correction.
- Standalone Q2 FY26 revenue rose to ₹9,942.42 lakhs, up from ₹5,900.92 lakhs in Q2 FY25.
- Standalone Q2 FY26 net profit surged to ₹990.85 lakhs from ₹235.19 lakhs in the same period last year.
- Subsidiaries reported a total net loss of ₹4,628.24 lakhs for the half-year ended September 30, 2025.
Zota Health Care Limited has announced the retirement of Mr. Ratilal Harkhani, who served as the Plant Manager and was designated as Senior Management Personnel (SMP). The retirement is effective from the close of business hours on March 31, 2026, in accordance with the company's superannuation policy. This is a routine administrative transition and not a resignation or termination. The company has complied with SEBI Regulation 30 regarding this disclosure, ensuring transparency in management changes.
- Mr. Ratilal Harkhani, Plant Manager and SMP, to retire effective March 31, 2026.
- The retirement follows the Company’s standard superannuation policy.
- The cessation of his role as SMP is effective from the closure of business hours on the specified date.
- The disclosure was made in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.
Zota Health Care Limited has informed the exchange that its trading window will be closed starting April 1, 2026, for all designated persons including promoters and directors. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the company's annual financial results. The window will remain shut until 48 hours after the declaration of the audited financial results for the quarter and year ending March 31, 2026. The specific date for the board meeting to approve these results is yet to be announced.
- Trading window closure begins on April 1, 2026, for all insiders and designated employees.
- Closure pertains to the upcoming Audited Financial Results for the quarter and year ended March 31, 2026.
- The window will reopen 48 hours after the official announcement of the financial results.
- The board meeting date for results approval will be communicated separately in due course.
Zota Health Care Limited has issued a postal ballot notice to seek shareholder approval for a special resolution under Section 186 of the Companies Act. The company is requesting authorization for the Board to provide loans, guarantees, or acquire securities up to a maximum limit of ₹1,000 Crores. This proposed limit exceeds the standard statutory thresholds of 60% of paid-up capital and reserves or 100% of free reserves. The e-voting period for shareholders is scheduled from March 18, 2026, to April 16, 2026.
- Proposed aggregate limit for loans, guarantees, and investments set at ₹1,000 Crores.
- Resolution seeks to exceed the standard 60% of paid-up capital/reserves or 100% of free reserves limit.
- Remote e-voting period spans from March 18, 2026, to April 16, 2026.
- Final voting results to be declared on or before April 17, 2026.
Zota Health Care's Board has approved a proposal to seek shareholder consent via postal ballot to increase limits for loans, guarantees, and investments under Section 186 of the Companies Act, 2013. This move indicates the company is preparing for potential strategic investments or providing financial support to other entities beyond current statutory limits. The cut-off date for voting eligibility was set for March 13, 2026, with the e-voting period concluding on April 16, 2026. Investors should monitor the specific limit amounts and the intended purpose once the detailed postal ballot notice is released.
- Board approved seeking shareholder approval to exceed Section 186 limits for loans, guarantees, and securities.
- Cut-off date for determining voting rights for the Postal Ballot is March 13, 2026.
- E-voting period is scheduled to run from March 18, 2026, to April 16, 2026.
- Mr. Ranjit B. Kejriwal has been appointed as the Scrutinizer for the voting process.
- Final results of the postal ballot are expected to be declared by April 17, 2026.
Zota Health Care, through its subsidiary Everyday Herbal Beauty Care Limited, is launching a new national retail chain called "All Day Stores" (ADS). The expansion begins with 50 outlets in the first phase, with 15 stores scheduled to open on March 07, 2026, across five Indian states including Gujarat and Maharashtra. Each store will feature over 430 SKUs of private-label products, including personal care and household essentials, in formats ranging from 500 to 1000 square feet. This move represents a strategic forward-integration effort to diversify revenue beyond its existing generic medicine chain, Davaindia.
- Launch of 'All Day Stores' (ADS) retail chain via subsidiary Everyday Herbal Beauty Care Limited
- Phase 1 expansion includes 50 outlets, with the first 15 stores opening on March 07, 2026
- Stores will offer over 430 SKUs of private-label products across personal care, OTC, and essentials
- Initial rollout covers key markets in Gujarat, West Bengal, Maharashtra, Karnataka, and Delhi
- Store sizes optimized between 500 to 1000 square feet to ensure a comfortable shopping experience
Zota Health Care Limited has scheduled an interaction with institutional investors and analysts on March 6, 2026. The meeting is organized by Nirmal Bang Institutional Equities and will be conducted via video conference. The company will engage in one-on-one or group discussions regarding business updates. Management has clarified that only information already in the public domain will be discussed, ensuring no unpublished price sensitive information is shared.
- Investor meeting scheduled for Friday, March 6, 2026.
- Organized by Nirmal Bang Institutional Equities via video conference.
- Format includes both one-on-one and group interaction sessions.
- Discussions will be limited to business presentations already available on stock exchange websites.
- Compliant with Regulation 30(6) of SEBI (LODR) Regulations, 2015.
Zota Health Care has approved the grant of 16,394 stock options to eligible employees under its 2022 ESOP scheme. These options are exercisable at the face value of Rs. 10 per share, which serves as a significant retention incentive. The vesting is spread over five years, with a front-loaded schedule where 75.6% of the options vest after the first year. This grant brings the total unexercised options under this specific plan to 123,124 out of a total authorized pool of 250,000 shares.
- Grant of 16,394 stock options at an exercise price of Rs. 10 per share (Face Value).
- Vesting schedule: 75.60% after 1 year, 9.76% after 3 years, and 14.64% after 5 years.
- Cumulative options granted under the 2022 plan reach 127,124, with 123,124 currently unexercised.
- The total ESOP 2022 pool is limited to 250,000 equity shares, representing a small fraction of total equity.
Zota Health Care has significantly increased its ownership in its subsidiary, Everyday Herbal Beauty Care Limited (EHBCL), by acquiring an additional 21.80% stake. The acquisition was executed via a rights issue subscription for a total consideration of Rs 19.47 crore at Rs 16.50 per share. This transaction raises Zota's total shareholding in EHBCL to 87.78%, up from approximately 66%. EHBCL, which manufactures products under the 'Khadi India' brand, showed robust growth with turnover jumping from Rs 73.39 lakhs in FY24 to Rs 1,144.22 lakhs in FY25.
- Acquired 1,18,00,000 equity shares representing a 21.80% stake in subsidiary EHBCL.
- Total investment of Rs 19.47 crore at an acquisition price of Rs 16.50 per share.
- Post-acquisition shareholding in EHBCL has increased to 87.78%.
- EHBCL reported a significant turnover growth to Rs 1,144.22 lakhs in FY 2024-25.
- The move is intended to strengthen backward integration in the cosmetic, ayurvedic, and OTC segments.
Zota Health Care has reached a significant milestone with its Davaindia network growing to 2,502 operational stores as of February 11, 2026. This represents a rapid addition of 171 stores since December 31, 2025, when the count stood at 2,331. The current network is comprised of 1,607 Company Owned Company Operated (COCO) stores and 895 Franchisee Owned Franchisee Operated (FOFO) stores. For the current fiscal year, the company has added a total of 920 stores, with a strategic focus on the COCO model which accounted for 755 of those additions.
- Total operational stores reached 2,502 as of February 11, 2026, up from 2,331 in December 2025
- Added 920 stores in the current fiscal year, including 755 COCO and 165 FOFO units
- COCO stores now make up the majority of the network with 1,607 operational units
- The network expansion demonstrates a high execution rate with 171 stores added in approximately 40 days
- Strategic focus remains on providing affordable generic medicines through a mix of owned and franchised outlets
Zota Health Care has allotted 5,71,961 equity shares to 11 non-promoter investors upon the conversion of the final batch of warrants. The company received Rs. 21.83 Crores as exercise money, representing 75% of the total issue price of Rs. 509 per share. This allotment increases the total paid-up equity capital to Rs. 34.63 Crores. With this conversion, the company has successfully closed the warrant issue initiated in August 2024, with no outstanding warrants remaining.
- Allotment of 5,71,961 equity shares at Rs. 509 per share (including Rs. 499 premium).
- Infusion of Rs. 21.83 Crores in capital from 11 non-promoter group investors.
- Total paid-up capital increased from 3.40 Crore to 3.46 Crore equity shares.
- Zero outstanding warrants remain from the original 26.44 lakh warrant issue.
Zota Health Care reported a robust 98.2% YoY revenue growth in Q3FY26, reaching INR 142.95 crore, driven by the aggressive expansion of its Davaindia network. The company added 276 stores during the quarter, bringing the total count to 2,331, while successfully raising INR 350 crore via QIP to fund future growth. Although EBITDA was impacted by pre-operative expenses for approximately 400 stores in the pipeline, management remains confident in reaching 5,000 stores by March 2029. Strategic moves include the acquisition of Curexis and the formation of a new marketing subsidiary to optimize margins.
- Consolidated revenue surged 98.2% YoY to INR 142.95 crore, with Davaindia contributing 80% of total sales.
- Added 276 new stores in Q3, taking the total Davaindia footprint to 2,331 stores across 23 states and 5 UTs.
- Successfully completed a INR 350 crore QIP to accelerate the rollout of Company-Owned Company-Operated (COCO) stores.
- Quarterly customer footfall nearly doubled to 49 lakhs compared to 27 lakhs in the previous year.
- Acquired 100% stake in Curexis (SKIA brand) and incorporated KMHP Ventures for better sourcing and distribution.
Zota Health Care Limited has officially released the audio recording of its earnings conference call held on February 05, 2026. The call addressed the company's operational and financial performance for the third quarter ended December 31, 2025. This disclosure is part of the company's regulatory compliance under SEBI (LODR) Regulations, 2015. Investors can access the recording via the provided Google Drive link to gain insights into management's commentary on the quarter's results.
- Audio recording of the Q3FY26 earnings call made available to the public on February 05, 2026.
- The call discussed financial and operational performance for the quarter ended December 31, 2025.
- Compliance filing under Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Recording link is accessible via the company's website and a direct Google Drive link.
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 62% YoY in FY25 to INR 29,298 lakhs. The Davaindia vertical grew 80% YoY to INR 18,621 lakhs (64% of total), Domestic Sales grew 11% YoY to INR 6,342 lakhs (22% of total), and the Export Business grew 59% YoY. In Q2 FY26, consolidated revenue reached INR 12,895 lakhs, a 92% increase from INR 6,727 lakhs in Q2 FY25.
Geographic Revenue Split
Domestic operations (including Davaindia and standard domestic sales) contribute approximately 86% of total revenue (INR 24,963 lakhs in FY25), while the Export segment, operating in over 30 countries from the Sachin SEZ facility, contributes the remaining balance, having grown 59% in the last fiscal year.
Profitability Margins
Gross profit for Q2 FY26 stood at INR 7,650 lakhs, reflecting a 112% YoY growth. Gross margins for franchisee stores are structured with a 37% upfront margin, resulting in a GMV-to-revenue ratio of approximately 55%. For mature stores (3+ years), the franchisee margin adjusts to 26%.
EBITDA Margin
EBITDA turned positive in Q2 FY26 at INR 796 lakhs (approx. 6.17% margin) compared to a loss of INR 32 lakhs in Q2 FY25. This turnaround is driven by improved scale in the Davaindia vertical and disciplined cost management despite a INR 10 crore increase in other expenses.
Capital Expenditure
The company raised funds through a preferential issue in July 2024 to fund expansion. While specific total INR Cr for future CapEx is not disclosed, the company is utilizing these funds for the Davaindia rollout, with monitoring by CRISIL Ratings Limited.
Credit Rating & Borrowing
CRISIL Ratings Limited acts as the monitoring agency for fund utilization. Debt levels were reduced in FY25 compared to FY24 due to the fresh equity infusion from preferential issues, though debt service obligations increased YoY due to expansion activities.
Operational Drivers
Raw Materials
Pharmaceutical formulations and generic medicines represent the primary cost of goods sold, accounting for approximately 40-45% of revenue based on the 55% GMV-to-revenue conversion for franchisee models.
Import Sources
Not disclosed in available documents; however, the company operates a manufacturing facility in the Sachin Special Economic Zone (SEZ), Gujarat, for international formulations.
Capacity Expansion
The company aims to open 500 to 800 new stores in FY27. Current workforce stands at 3,307 employees (520 in ZOTA corporate and 2,787 in Davaindia Health Mart) to support this retail footprint expansion.
Raw Material Costs
Not explicitly disclosed as a separate line item, but gross profit growth of 112% outpaced revenue growth of 92% in Q2 FY26, suggesting improved procurement efficiencies and a higher share of high-margin generic private labels.
Manufacturing Efficiency
The company leverages its Sachin SEZ facility for global formulations, securing product approvals in over 30 countries to optimize manufacturing overheads through export volume.
Logistics & Distribution
Distribution is handled through a multi-tier intermediary system to ensure nationwide accessibility of affordable pharmaceuticals.
Strategic Growth
Expected Growth Rate
80%
Growth Strategy
Growth is driven by the aggressive expansion of the Davaindia retail chain, targeting 500-800 new stores in FY27 and a revenue target of INR 520-540 Cr for FY26. The strategy relies on onboarding high-profile brand ambassadors like M.S. Dhoni and Suniel Shetty to build trust in generic medicines and leveraging the 'Khadi' mark for brand authenticity.
Products & Services
Generic medicines, affordable healthcare solutions, and pharmaceutical formulations sold through COCO (Company Owned Company Operated) and FOFO (Franchisee Owned Franchisee Operated) retail stores.
Brand Portfolio
Davaindia, Zota Health Care.
New Products/Services
Expansion of the 'Khadi' marked product line and private label generics which typically offer higher margins than branded substitutes.
Market Expansion
Targeting Tier II and beyond, where organized pharmacy penetration is currently only 10%, compared to 28% in Metros.
Market Share & Ranking
Organized pharmacy retail is projected to grow from 10% in FY25 to 25% by FY30; Zota aims to capture this shift from the 90% unorganized market.
Strategic Alliances
Partnership with CRISIL for fund monitoring and brand associations with M.S. Dhoni and Suniel Shetty.
External Factors
Industry Trends
The industry is shifting from unorganized (90% in FY20) to organized retail (projected 25% by FY30). Zota is positioning Davaindia to capitalize on this 15% market share shift by focusing on affordability and omni-channel readiness.
Competitive Landscape
Competes with unorganized local pharmacies and emerging organized players. Zota differentiates through a 100% private label share in Davaindia stores compared to 5-20% in other organized pharmacies.
Competitive Moat
The moat is built on brand credibility (Dhoni/Shetty endorsements), the 'Khadi' mark certification, and a first-mover advantage in the large-scale generic-only retail space in India. This is sustainable due to the high cost and time required to build a 1,000+ store network.
Macro Economic Sensitivity
Highly sensitive to healthcare spending trends and the shift toward organized retail. Rising urbanization and improved digital infrastructure are cited as 10% and 5% growth drivers respectively for the organized pharmacy sector.
Consumer Behavior
Increasing consumer preference for affordable generic medicines over expensive branded alternatives, supported by government initiatives like Jan Aushadhi (PIB Source).
Geopolitical Risks
Export operations in semi-regulated and regulated markets are subject to trade barriers and changing international pharmaceutical standards.
Regulatory & Governance
Industry Regulations
Operations are governed by extensive pharmaceutical regulations in India and 30+ export countries. Compliance with manufacturing standards at the Sachin SEZ facility is critical for maintaining international product approvals.
Risk Analysis
Key Uncertainties
The 'Growth Phase' pressure: Management notes that rapid expansion (500-800 stores/year) may keep EBITDA and PAT under pressure in the short term (FY26-27) despite high revenue growth.
Geographic Concentration Risk
Heavy concentration in India, specifically Gujarat (Surat headquarters), though expanding nationally through the Davaindia vertical.
Third Party Dependencies
High dependency on FOFO partners; if franchisee profitability (currently ~INR 30,000/month) drops, store closures could accelerate.
Technology Obsolescence Risk
The company is focusing on 'Omni-channel readiness' to mitigate the risk of losing market share to e-pharmacies.
Credit & Counterparty Risk
Low risk in Davaindia due to the retail cash model, but standard domestic and export segments carry inherent credit risks from stockists and international distributors.